Browse by author
Lookup NU author(s): Professor Sophie HambletonORCiD
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
© 2024 American Academy of Allergy, Asthma & Immunology. Background: CD4+ T cells play essential roles in adaptive immunity. Distinct CD4+ T-cell subsets—TH1, TH2, TH17, TH22, T follicular helper, and regulatory T cells—have been identified, and their contributions to host defense and immune regulation are increasingly well defined. IL-9–producing TH9 cells were first described in 2008 and appear to play both protective and pathogenic roles in human immunity. However, key requirements for generating human TH9 cells remain incompletely defined. Objective: We sought to define signaling pathways that regulate IL-9 production by human CD4+ T cells. Methods: Human naive and memory CD4+ T cells were cultured under different conditions, and the molecular mechanisms regulating IL-9 induction were determined by assessing the ability of CD4+ T cells from a broad range of patients (n = 92) with pathogenic variants in key immune genes (n = 21) to differentiate into IL-9+ cells. Results: We identified 2 culture conditions that yielded IL-9–expressing cells from naive CD4+ T cells and amplified IL-9 production by in vivo–generated memory CD4+ T cells: TGF-β plus IL-4 (ie, TH9 polarizing condition), and the combination of IL-21, IL-23, IL-6, IL-1β, and TGF-β (ie, TH17 polarizing condition). Combining these conditions had a synergistic effect in generating IL-9+CD4+ T cells. IL-9 induction required STAT3-activating cytokines as well as intact signaling via the T-cell receptor and STAT5. Importantly, IL-9 induction was restrained by IFN-γ/STAT1 and IL-10. Conclusions: Our findings revealed critical molecules involved in inducing/restraining IL-9 production by human CD4+ T cells, thereby identifying pathways that could be targeted to modulate IL-9 in health and disease.
Author(s): Rao G, Mack CD, Nguyen T, Wong N, Payne K, Worley L, Gray PE, Wong M, Hsu P, Stormon MO, Preece K, Suan D, O'Sullivan M, Blincoe AK, Sinclair J, Okada S, Hambleton S, Arkwright PD, Boztug K, Stepensky P, Cooper MA, Bezrodnik L, Nadeau KC, Abolhassani H, Abraham RS, Seppanen MRJ, Beziat V, Bustamante J, Forbes Satter LR, Leiding JW, Meyts I, Jouanguy E, Boisson-Dupuis S, Uzel G, Puel A, Casanova J-L, Tangye SG, Ma CS
Publication type: Article
Publication status: Published
Journal: Journal of Allergy and Clinical Immunology
Year: 2025
Volume: 115
Issue: 4
Pages: 1161-1178
Print publication date: 01/04/2025
Online publication date: 30/11/2024
Acceptance date: 25/11/2024
ISSN (print): 0091-6749
ISSN (electronic): 1097-6825
Publisher: Elsevier Inc.
URL: https://doi.org/10.1016/j.jaci.2024.11.031
DOI: 10.1016/j.jaci.2024.11.031
PubMed id: 39622295
Altmetrics provided by Altmetric
